Medicinsk behandling
Studie finner att lecanemab rensar amyloid men visar ingen korttidsåterhämtning i hjärnans avfallsrensningssystem
Rapporterad av AI Bild genererad av AI Faktagranskad
Forskare vid Osaka Metropolitan University rapporterar att medan Alzheimers läkemedlet lecanemab minskar amyloidplack, visade MRI-mätningar ingen förbättring i hjärnans glymfatiska avfallsrensning tre månader efter att behandlingen påbörjades, vilket understryker sjukdomens komplexitet och behovet av multifokuserade tillvägagångssätt.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Rapporterad av AI
Judy Wanyoike was diagnosed with stage 2B cervical cancer in 2012 following a Pap Smear test. Despite surgery, chemotherapy, and radiation therapy, the cancer returned in 2019 and again in 2022. Experts stress the need for early detection to prevent recurrence.